A study published today by Oxford Academic’s Journal of Pharmacy and Pharmacology finds that cannabidiol (CBD), when delivered through a folic acid-modified chitosan (FA-CS) nanoparticle system, significantly inhibited tumor growth in triple-negative breast cancer (TNBC), an aggressive form of the disease with few effective treatment options.
Researchers from Sun Yat-sen University, Zunyi Medical University, and the Sun Yat-sen University Cancer Center developed and tested FA-CS@CBD nanoparticles designed to improve CBD’s solubility, distribution, and targeted delivery. The nanoparticles were uniform in size, stable, and demonstrated strong cellular uptake.
In laboratory tests on 4T1 breast cancer cells, the CBD nanoparticles outperformed free CBD by increasing reactive oxygen species production, promoting apoptosis, and reducing cancer cell migration. In animal models, the nanoparticle system achieved a tumor inhibition rate of 68.07% while showing minimal systemic toxicity, underscoring its safety profile.
The authors concluded that the nanoparticle-based system improved the therapeutic effects of CBD and provided enhanced tumor-targeting compared to conventional administration. They noted that this approach could expand the clinical application of CBD in breast cancer therapy, particularly for TNBC patients who currently face limited treatment pathways.
More articles from The Marijuana Herald:
